Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Elena N Simakina"'
Autor:
Andrey A. Ivashchenko, Valeria N. Azarova, Alina N. Egorova, Ruben N. Karapetian, Dmitry V. Kravchenko, Natalia V. Krivonos, Vladimir G. Loginov, Stanislav V. Poyarkov, Elena A. Merkulova, Olga S. Rosinkova, Nikolay P. Savchuk, Mikhail A. Topr, Elena N. Simakina, Elena V. Yakubova, Alexandre V. Ivachtchenko
Publikováno v:
Viruses, Vol 13, Iss 7, p 1253 (2021)
COVID-19 is a contagious multisystem inflammatory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied the efficacy of Aprotinin (nonspecific serine proteases inhibitor) in combination with Avifavir® or Hydrox
Externí odkaz:
https://doaj.org/article/bdadf2eb06b245cbb92ee84869032a4d
Autor:
Kira Yа Zaslavskaya, Konstantin Kolontarev, Alina S. Agafina, D. Pushkar, L. A. Balykova, Marina V. Granovskaya, Anastasiya Y. Ivanova, Elena N. Simakina
Publikováno v:
Infectious diseases: News, Opinions, Training. 9:16-29
The aim - to study the efficacy and safety of favipiravir (Areplivir) in patients with novel coronavirus infection (COVID-19) in comparison with the recommended standard therapy Material and methods 200 men and women with COVID-19 between the ages of
Autor:
Stanislav V Poyarkov, Natalia V Krivonos, Elena N Simakina, Olga S Rosinkova, Elena A. Merkulova, Nikolay Filippovich Savchuk, Dmitry V. Kravchenko, Alina N. Egorova, Valeria N Azarova, Elena V Yakubova, Ruben N. Karapetian, Alexandre V. Ivachtchenko, Mikhail A Topr, Andrey Alexandrovich Ivashchenko, Vladimir G Loginov
Publikováno v:
Viruses, Vol 13, Iss 1253, p 1253 (2021)
Viruses
Viruses
COVID-19 is a contagious multisystem inflammatory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied the efficacy of Aprotinin (nonspecific serine proteases inhibitor) in combination with Avifavir® or Hydrox
Autor:
Elena A Smolyarchuk, Natalia V. Vostokova, Andrew A. Blinow, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Nikolay Filippovich Savchuk, Tagir A. Sitdekov, Elena A. Merkulova, Kirill A. Dmitriev, Elena N Simakina, Elena P. Pavlikova, Valeria N Azarova, Natalia A. Papazova, Andrey Alexandrovich Ivashchenko, Alexandre V. Ivachtchenko, Alina N. Egorova, Nikita V. Lomakin, Dmitry V. Kravchenko, Alexey P. Ilin, Ivan G. Gordeev
Publikováno v:
Clinical Infectious Diseases
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-
Autor:
Ivan G. Gordeev, Andrey Alexandrovich Ivashchenko, Alexey P. Ilin, Dmitry V. Kravchenko, Nikolay Filippovich Savchuk, Kirill A. Dmitriev, Nikita V. Lomakin, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Elena N Simakina, Elena A. Merkulova, Natalia V. Vostokova, Natalia A. Papazova, Elena A Smolyarchuk, Alexandre V. Ivachtchenko, Andrew A. Blinow, Elena P. Pavlikova, Tagir A. Sitdekov, Alina N. Egorova, Valeria N Azarova
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4c74b1b527e94b4d82f6b1475524f5